Item 2.02 Results of Operations and Financial Condition.

On May 10, 2021, Adamas Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits
Exhibit No.             Description
  99.1                  99.1 Press Release dated May 10, 2021.
104                     Cover Page Interactive Data File (embedded within the Inline XBRL document).



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses